Tech Company Financing Transactions

Alimera Sciences Funding Round

Alimera Sciences, operating out of Alpharetta, raised $31.8 million from Venrock, Bank of America and Domain Associates.

Transaction Overview

Company Name
Alimera Sciences
Announced On
12/1/2005
Transaction Type
Venture Equity
Amount
$31,800,000
Round
Series B
Investors

Venrock (Lead Investor) (Daniel Myers)

Bank of America

Domain Associates (Brian Halak)

Intersouth Partners (Philip Tracy)

Polaris Partners (Bryce Youngren)

Scale Venture Partners (Mark Brooks)

Proceeds Purpose
The new funding arrives about two months after Alimera said it had commenced Phase-3 clinical trials on a pharmaceutical treatment for vision loss related to diabetes. The substance treats diabetic macular edema, a retinal disorder that occurs in as many as a fourth of diabetes patients.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
6120 Windward Pkwy. 290
Alpharetta, GA 30005
USA
Phone
(678) 990-5740
Website
www.alimerasciences.com
Email Address
[email protected]
Overview
Biopharmaceutical company that researches, develops and commercializes prescription ophthalmic pharmaceuticals with a focus on the back of the eye, or retina.
Profile
Alimera Sciences LinkedIn Company Profile
Social Media
Alimera Sciences Company Twitter Account
Company News
Alimera Sciences News
Facebook
Alimera Sciences on Facebook
YouTube
Alimera Sciences on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Rick Eiswirth
  Rick Eiswirth LinkedIn Profile  Rick Eiswirth Twitter Account  Rick Eiswirth News  Rick Eiswirth on Facebook
Chief Financial Officer
Philip Jones
  Philip Jones LinkedIn Profile  Philip Jones Twitter Account  Philip Jones News  Philip Jones on Facebook
Chief Medical Officer
Samer Kaba
  Samer Kaba LinkedIn Profile  Samer Kaba Twitter Account  Samer Kaba News  Samer Kaba on Facebook
Chief Operating Officer
Philip Ashman
  Philip Ashman LinkedIn Profile  Philip Ashman Twitter Account  Philip Ashman News  Philip Ashman on Facebook
VP - Marketing
Dave Holland
  Dave Holland LinkedIn Profile  Dave Holland Twitter Account  Dave Holland News  Dave Holland on Facebook

 

 

Browse more venture capital transactions:

Prev: 12/1/2005: NeurogesX venture capital transaction
Next: 12/2/2005: mValent venture capital transaction

 

Share this article

 

Where The Data Comes From

We record all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.